Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

AREXVY

Phase 2Biologic

CClover Biopharmaceuticals AUS Pty

1

Indications

4

Total Trials

3

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

ImmunocompromisedRecruiting

ImmunocompromisedPhase 2

Recruiting

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Vaccine

NCT06556147

Q2 2028

Phase 2Recruiting

Immunocompromised

NCT07050732

Clinical

Trials by Indication[1]

Immunogenicity2 trials

Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults

Recruiting·CClover Biopharmaceuticals USA, LLC·Phase 1·NCT06843317·160 enrolled

First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults

Completed·CClover Biopharmaceuticals AUS Pty·Phase 1·NCT06194318·160 enrolled

Vaccine1 trial

A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults

Active, not recruiting·VVicebio Australia Proprietary Limited·Phase 1·NCT06556147·144 enrolled

Immunocompromised1 trial

Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons

Recruiting·JJohns Hopkins University·Phase 2·NCT07050732·170 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for AREXVY. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AREXVY compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AREXVY. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Clover Biopharmaceuticals AUS Pty company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: CClover Biopharmaceuticals AUS Pty

Related News